Dr. Hartman discusses diabetes, hyperlipidemia and obesity, and why it is crucial to treat obesity as a clinical condition, not a willpower issue.

In this Exclusive Interview, Dr. Hartman discuss practical points in the approach of the patient with diabetes, hyperlipidemia and obesity.

In this week's Homerun Slides, the initiation of basal insulin.

Intravenous glucose: In the presence of euglycemia, insulin displays a potent suppressive action on hepatic glucose production, such that portal insulin concentrations of less than 100 mU L−1 abolish glucose entry into the circulation. Figure 14.7 shows a typical time course for endogenous glucose production following an acute increase in plasma insulin to levels of 60 – 70 mU L−1 in a healthy subject.

There just doesn’t seem to be enough time to cover everything that we got to see at the recent Scientific Sessions in San Diego. Since the ADA draws in scientists and researchers from around the world, it is the number-one place to present new findings both good and bad. In …

Medical pioneer has educated his diabetes patients on how to get blood sugars to 83mg/dl, 24 hours a day

The Endocrinologic and Metabolic Drugs Advisory Committee also voted 19-0 that the drug's use in type 2 diabetes patients did not result in excess cardiovascular risk.

Research will still continue due to its safety.

However, in 2016, Novo Nordisk halted the development of their basal oral insulin tablet.

Results presented in the ADA 77th Scientific Sessions suggests the use of an investigational glucagon-blocking agent can improve glycemic levels and reduce insulin requirements.